Search

Kristin M Defife

from San Diego, CA
Age ~55
Get Report
Also known as:
Kristin M Fife
Phone and address:
4917 Chaucer Ave, San Diego, CA 92120
(619) 287-2468
Related to:
Linda S Roth, 77Ruth I Shelton, 71Nicole DefifeKenneth Easterwood, 80Michael R Wallin, 50
Connected to:
Jacqueline M Defigh, 73Joshua Defigueiredo, 49Thomas M Defile, 60Adam J Defilippo, 48Andrea J Defilippo, 64Andrew J Defilippis, 52Anthony R Defilippo, 52Brande A Defilippis, 50Brittany S Defilippo, 33Carla M Defilippo, 63

Kristin Defife Phones & Addresses

  • 4917 Chaucer Ave, San Diego, CA 92120 (619) 287-2468
  • Cleveland, OH
  • 2195 Station Village Way, San Diego, CA 92108 (619) 977-1892

Work

Company: Ajinomoto bio-pharma services Oct 2018 Position: Senior vice president of operations and site head

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Case Western Reserve University 1991 to 1996 Specialities: Philosophy

Skills

Biotechnology • R&D • Manufacturing • Biopharmaceuticals • Fda • Life Sciences • Gmp • Technology Transfer • Lifesciences • Protein Chemistry

Industries

Biotechnology

Resumes

Resumes

Kristin Defife Photo 1

Senior Vice President Of Operations And Site Head

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
Ajinomoto Bio-Pharma Services
Senior Vice President of Operations and Site Head
Althea, Cmo Apr 1, 2012 - Oct 2018
V.p and Head of Us Operations
Pacificgmp May 2008 - Apr 2012
V.p Operations
Medivas Llc Dec 2003 - Apr 2008
V.p R and D
Immusol Apr 2000 - Nov 2003
Project Leader
Education:
Case Western Reserve University 1991 - 1996
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Biotechnology
R&D
Manufacturing
Biopharmaceuticals
Fda
Life Sciences
Gmp
Technology Transfer
Lifesciences
Protein Chemistry

Business Records

Name / Title
Company / Classification
Phones & Addresses
Kristin Defife
Vice-President
Pacific Gmp
Whols Industrial Equipment · Research & Development in Biotechnology
8810 Rehco Rd, San Diego, CA 92121
(858) 550-4095, (858) 550-4094

Publications

Us Patents

Bioactive Stents For Type Ii Diabetics And Methods For Use Thereof

View page
US Patent:
8163269, Apr 24, 2012
Filed:
Apr 4, 2005
Appl. No.:
11/098891
Inventors:
Kenneth W. Carpenter - San Diego CA, US
William G. Turnell - San Diego CA, US
Kristin M. DeFife - San Diego CA, US
Kathryn A. Grako - San Diego CA, US
International Classification:
A61M 36/14
A61K 51/00
US Classification:
424 169, 424 111, 424 165, 424 91, 514 11
Abstract:
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

Bioactive Stents For Type Ii Diabetics And Methods For Use Thereof

View page
US Patent:
20060013855, Jan 19, 2006
Filed:
Jun 7, 2005
Appl. No.:
11/147994
Inventors:
Kenneth Carpenter - San Diego CA, US
William Turnell - San Diego CA, US
Kristin DeFife - San Diego CA, US
Kathryn Grako - San Diego CA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
A61F 2/00
US Classification:
424423000
Abstract:
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

Vaccine Delivery Compositions And Methods Of Use

View page
US Patent:
20060188469, Aug 24, 2006
Filed:
Jan 31, 2006
Appl. No.:
11/345021
Inventors:
William Turnell - San Diego CA, US
Vassil Vassilev - San Diego CA, US
Kristin DeFife - San Diego CA, US
Hong Li - San Diego CA, US
Zaza Gomurashvili - San Diego CA, US
Ramaz Katsarava - Tbilisi GA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
A61K 39/00
US Classification:
424078270, 424185100
Abstract:
The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion of polymer particles or molecules including class I or class II antigen peptides derived from organism or tumor cell proteins, which are taken up by antigen presenting cells of the mammal to induce an immune response in the mammal. Methods of inducing an immune response to the pathogenic organism or tumor cells in the invention compositions are also included.

Polymer Particles For Delivery Of Macromolecules And Methods Of Use

View page
US Patent:
20070134332, Jun 14, 2007
Filed:
Nov 21, 2006
Appl. No.:
11/603660
Inventors:
William Turnell - San Diego CA, US
Geoffrey Landis - Carlsbad CA, US
Zaza Gomurashvili - La Jolla CA, US
Hong Li - San Diego CA, US
Kristin DeFife - San Diego CA, US
Vassil Vassilev - San Diego CA, US
Yumin Yuan - San Diego CA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
A61K 48/00
A61K 38/28
C08F 20/00
A61K 9/14
US Classification:
424486000, 514003000, 514004000, 525440000, 514044000
Abstract:
The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated either as a liquid dispersion or a lyophilized powder of polymer particles containing bound water molecules with the macromolecular biologics, for example insulin, dispersed in the particles. Bioactive agents, such as drugs, polypeptides, and polynucleotides can also be delivered by using particles sized for local, oral, mucosal or circulatory delivery. Methods of delivering a macromolecular biologic with substantial native activity to a subject, for example orally, are also included.

Bioactive Wound Dressings And Implantable Devices And Methods Of Use

View page
US Patent:
20080020015, Jan 24, 2008
Filed:
Apr 26, 2007
Appl. No.:
11/796267
Inventors:
Kenneth Carpenter - La Jolla CA, US
William Turnell - San Diego CA, US
Kristin DeFife - San Diego CA, US
Kathryn Grako - San Diego CA, US
Ramaz Katsarava - Tbilisi GA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
A61K 35/12
A61F 13/00
A61K 9/00
A61P 17/02
US Classification:
424426000, 424422000, 424445000, 424093700
Abstract:
The present invention provides wound dressings, optionally surgically implantable, containing biodegradable, polymers and hydrogels having allogenic or autologous precursor cells, such as stem cells and progenitor cells dispersed within. Alternatively, the wound dressings can have conditioned medium obtained from the precursor cells dispersed within. The wound dressings promote tissue restoration processes at a site of application or implantation. Additional bioactive agents can also be dispersed within the polymer/hydrogel matrix, which can be formulated to biodegrade at a controlled rate by adjusting the composition. Methods are also provided for using such biodegradable wound dressings as a delivery device or carrier for the precursor cells, conditioned medium and bioactive agents, or as coatings on implantable medical devices, to promote tissue restoration at a lesion site.

Vaccine Delivery Compositions And Methods Of Use

View page
US Patent:
20080160089, Jul 3, 2008
Filed:
Jan 31, 2007
Appl. No.:
11/701229
Inventors:
Maria A. Vitiello - La Jolla CA, US
Kristin M. DeFife - San Diego CA, US
William G. Turnell - Del Mar CA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
A61K 39/21
A61K 39/385
A61K 9/14
A61P 31/00
A61K 39/12
A61K 39/02
US Classification:
424489, 4241931, 4241861, 4241901, 4241881
Abstract:
The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants. The vaccines can be formulated as a liquid dispersion of polymer particles or molecules in which are dispersed an immunostimulatory adjuvant, such as a TLR agonist, and whole protein or peptidic antigens containing MHC class I or class II epitopes derived from organism or tumor cell proteins. Methods of inducing an immune response via intracellular mechanisms to the pathogenic organism or tumor cells specific for the antigen in the invention compositions are also included.

Bioactive Stents For Type Ii Diabetics And Methods For Use Thereof

View page
US Patent:
20080288057, Nov 20, 2008
Filed:
Apr 4, 2006
Appl. No.:
11/885791
Inventors:
Kenneth W. Carpenter - San Diego CA, US
William G. Turnell - San Diego CA, US
Kristin M. Defife - San Diego CA, US
Kathryn A. Grako - San Diego CA, US
International Classification:
A61F 2/82
A61F 2/24
US Classification:
623 142, 623 242, 424426
Abstract:
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

Cationic Alpha-Amino Acid-Containing Biodegradable Polymer Gene Transfer Compositions

View page
US Patent:
20090068743, Mar 12, 2009
Filed:
Aug 22, 2008
Appl. No.:
12/197068
Inventors:
William G. Turnell - San Diego CA, US
Gina Ann Cruz-Aranda - Bonita CA, US
Mark MinZhi Wu - San Diego CA, US
Ronald Lee Chantung - San Diego CA, US
Zaza D. Gomurashvili - La Jolla CA, US
Kristin M. DeFife - San Diego CA, US
Assignee:
MediVas, LLC - San Diego CA
International Classification:
C12N 15/87
C12N 15/11
US Classification:
435455, 536 231
Abstract:
The invention provides gene transfer compositions using as the gene carrier a biodegradable polymer that contains one or more cationic alpha amino acids, such as arginine or agmatine. The compositions form a tight soluble complex with a poly nucleic acid suitable for transfecting target cells to effect translation of the cargo poly nucleic acid by the target cell. Thus, such compounds are useful both in vitro and in vivo.
Control profile
Kristin M Defife from San Diego, CA, age ~55 Get Report